Product Group | : | Parasiticides |
Pharmaceutical Form | : | Solution for Injection |
Active Ingredient | : | Buparvaquone |
Target Type | : | Cattle |
Package Form | : | 50 ml |
For Animal Use Only
For Animal Use Only
Solution for Injection
Veterinary Antiprotozooner
Buparcel Solution for Injection is a clear, red-dark brown sterile solution containing 50 mg of Buparvaquone in each ml.
Buparvaquone, the active ingredient of Buparcel Solution for Injection, is a second generation antiprotozooner from the hydroxynaphthoquinone group.
The tertiary-butyl bond in the composition of Buparcel Solution for Injection provides a long plasma half-life and the cyclohexyl ring in the 4-position ensures slow metabolism. Buparvaquone is effective on schizont and pyroplasma forms in cattle. Its activity is parasite-specific. It does not develop adverse effects on host lymphocytes. When buparvaquone is administered intramuscularly at a dose of 2.5 mg/kg, the maximum plasma concentration is 1.102 μg/kg, the time to peak plasma concentration is 3.27 hours, and the elimination half-life is 26.44 hours, and the volume of distribution is 35.381/kg. It is generally excreted in the stool after entero-hepatic circulation.
It is used in the treatment of all forms of Theileriosis caused by Theilleria annulata, T.parva, T.mutans, T.sergenti in cattle.
In cattle, it is administered only by deep intramuscular route from the neck muscle. Unless recommended otherwise by the Veterinarian,
Pharmacological dose: 2.5 mg/kg body weight.
Practical dose: 1 ml is applied per 20 kg body weight. If the dose is more than 10 ml, it should be divided into two.
A single dose is usually sufficient. In severe cases, a second dose may be required 48–72 hours after the first administration
In severe cases of Theileriosis, worsening of the disease may be observed despite treatment. In this case, the treatment needs to be repeated. It is useful to support the treatment with antibacterial application to prevent secondary infections. The possibility of the disease being mixed with other tick-borne diseases and co-occurring should be considered. It should be noted that other diseases masked by theileriosis symptoms may occur as the animal's immune system weakens. In case of Babesiosis and Anaplasmosis accompanying Theileriosis, specific treatment should be applied for these diseases. Convalescent animals develop immunity specific to the strain that caused the disease. However, a new infection may occur by an antigenically different strain. In this case, treatment with Buparvaquone should be repeated. During the convalescence period, importance should be given to the good nutrition of the animal. Seriously infected animals should not be exposed to stress factors such as long-term walking, transport, acaricide bath, etc. The presence of anemia is characteristic of theileriosis infections. Anemia should be considered in the treatment. It is necessary to spray the animals that have died from the disease with an appropriate acaricide and to kill the ticks that can transmit the disease on them. Care should be taken to ensure that the injection site is dry and clean. No more than 10 ml should be given to an injection site. In severe cases, if the application is repeated, injection should be made on the opposite side of the neck where the first application was made.
Temporary swelling and muscle spasms may be observed at the injection site after injection.
Theilleriosis suppresses the immune system and increases susceptibility to secondary bacterial infections. In this case, antibacterial drug treatment should be applied. For bacterial and viral vaccine applications, it is necessary to wait for recovery after treatment.
No specific symptoms have been reported in overdose.
Drug Residue Elimination Period: During the treatment and after the last drug use, cattle should not be sent to slaughter until 42 days after. It should not be used in dairy cattle whose milk is offered for human consumption.
It should only be used in the treatment of Theileriosis. It is not indicated for diseases of other blood parasites (Babesiosis and Anaplasmosis). It is not administered intravenously or subcutaneously.
Use in pregnancy: Not recommended for use during pregnancy.
Consult your veterinarian before use and in case of an unexpected effect. Keep out of reach of children and away from foodstuffs. Do not buy or use products whose shelf life has expired and whose packaging is damaged.
Protect from light. Store in its own package at room temperature not exceeding 25˚C (15˚C-25˚C). Shelf life is 2 years from the date of manufacture.
It is offered for sale in amber-colored glass bottles of 20 ml, 50 ml, and 100 ml in cardboard boxes.
Sold in veterinary offices and pharmacies with a veterinarian's prescription.
APPROVAL DATE OF THE PROSPECTUS: 22.03.2010
T.R. MINISTRY OF AGRICULTURE AND FORESTRY MARKETING PERMISSION DATE AND NO: 22.03.2010/22-058
Pİ FARMA İLAÇ SAN. VE TİC. A.Ş.
Malıköy Başkent OSB Mah. 26. Cad. No: 34/A - Sincan - ANKARA - TÜRKİYE
Pİ FARMA İLAÇ SAN. VE TİC. A.Ş.
Malıköy Başkent OSB Mah. 26. Cad. No: 34/A - Sincan - ANKARA - TÜRKİYE